The drug manufacturer lost the first trial in state court in Philadelphia over allegations that Risperdal causes gynecomastia or abnormal breast growth in boys and young men exposed to the popular antipsychotic drug.
The jury slapped Johnson & Johnson to pony up $2.5 million in compensatory damages to a young Alabama man blamed the company for promoting the “off label” use of Risperdal, which in turn resulted in gynecomastia.